Martin Hunt has over 30 years' experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising in the life science sector. His previous roles include CEO of biomaterials company Tissue Science Laboratories plc. Mr Hunt is Programme Director of the NIHR translational funding programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board.
Dr O'Neill is an accomplished biologist and a leader in human-bacterial interactions. Dr O'Neill previously founded a specialist dermatology business, Curapel Limited, leading the company through its formation and development stage. As an innovator and expert Dr O'Neill has worked as an adviser for a number of skincare businesses and brand owners. This includes delivering technology from the lab, through development and onto new product concepts in partnership with global corporations. Dr O'Neill is a biochemist by training and has previously led multidisciplinary research teams as a senior lecturer at the University of Manchester.
Doug Quinn has spent the last 15 years involved in start-up and early stage businesses helping to manage them through subsequent levels of growth and secure the requisite funding. Mr Quinn has operational experience both within finance and across other business functions as well as considerable corporate finance experience, including in public markets. He was previously CFO at AIM listed Arthro Kinetics Plc and is currently CFO with regenerative medicine company Videregen and prior to joining SkinBioTherapeutics was CFO with University of Manchester spinout Gelexir Healthcare.
Stephen O'Hara spent 20 years working for the National Health Service (NHS) where he was responsible for delivering microbiology services to a large university teaching hospital. Mr O'Hara left the NHS in 2000 to set up Acolyte Biomedica Limited (Acolyte), which developed rapid diagnostics for healthcare acquired infections such as MRSA. Acolyte was sold to 3M in 2007 where he became Director of Microbiology. Mr O'Hara left 3M in 2009 to become a Director at Taunton and Somerset Foundation Trust. In 2011 he founded Intelligent Biotech Limited as a vehicle to identify technologies and market opportunities in healthcare, which has enabled him to identify the emerging potential of the human microbiome and set up OptiBiotix.
Catherine has over two decades of experience in research, management and business in the biotechnology, pharmaceutical and venture capital sectors. Founder/Director of the consultancy Biolatris Ltd., Non-Executive Director of Videregen Ltd., Chair of the Trakcel Ltd Advisory Board, Translation Advisory Group member of the Babraham Institute, and Member of the Board of Trustees IMET2000. She is also a visiting professor at Kings College (London) teaching on the MSc programme 'Cellular Therapies from bench to market' and Senior Associate for the Masters in Bioscience Enterprise (Cambridge University).